Literature DB >> 23723055

Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Y Fang1, Y Ding, Q Guo, J Xing, Y Long, Z Zong.   

Abstract

BACKGROUND AND OBJECTIVES: The effective dose of radioiodine 131 (I-131) ablation for patients with differentiated thyroid cancer (DTC) after thyroidectomy was unclear, so we tried to find out which activity is the best using the methods of direct comparison and network meta-analyses.
METHODS: Direct comparison and network meta-analyses were conducted with ADDIS software. Randomized controlled trials (RCT) which compared different activities of I-131 after thyroidectomy for adult patients with DTC were included. The outcomes we evaluated were successful remnant ablation rate, duration of stay in an isolation unit, the number of subsequent I-131 treatments required, recurrence rate, and adverse effects.
RESULTS: Thirteen RCT (3352 patients) were included. Our network meta-analysis demonstrated that there were not any statistical differences in successful ablation rates among all comparisons except 100 mCi vs 15 mCi. However, rank probability plot suggested 60 mCi might be the best in successful ablation rate. For recurrence rate, both direct comparison and network meta-analyses showed no statistical differences among 100 mCi, 60 mCi, and 30 mCi; 100 mCi was associated with a smaller number of patients who required subsequent I-131 treatments and longer stay in an isolation unit than 30 mCi without any more adverse events.
CONCLUSION: Because of conflicting results between direct comparison and network meta-analyses, we failed to conclude which activity of I-131 is the best in successful ablation rates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23723055     DOI: 10.3275/8998

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

Review 1.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

2.  Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.

Authors:  Meltem Caglar; Fani M Bozkurt; Ceren Kapulu Akca; Sezen Elhan Vargol; Miyase Bayraktar; Omer Ugur; Ergun Karaağaoğlu
Journal:  Nucl Med Commun       Date:  2012-03       Impact factor: 1.690

3.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Authors:  Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

4.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

5.  A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer.

Authors:  Chandrasekhar Bal; Prem Chandra; Ajay Kumar; Sadanand Dwivedi
Journal:  Nucl Med Commun       Date:  2012-10       Impact factor: 1.690

6.  Checking consistency in mixed treatment comparison meta-analysis.

Authors:  S Dias; N J Welton; D M Caldwell; A E Ades
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

7.  Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.

Authors:  C S Bal; Ajay Kumar; G S Pant
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

8.  Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.

Authors:  Aleksandra Kukulska; Jolanta Krajewska; Marzena Gawkowska-Suwińska; Zbigniew Puch; Ewa Paliczka-Cieslik; Jozef Roskosz; Daria Handkiewicz-Junak; Michał Jarzab; Elzbieta Gubała; Barbara Jarzab
Journal:  Thyroid Res       Date:  2010-11-01

9.  Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.

Authors:  Apostolia Maria Tsimberidou; Christos Vaklavas; Sijin Wen; David Hong; Jennifer Wheler; Chaan Ng; Aung Naing; Susan Tse; Naifa Busaidy; Maurie Markman; Steven I Sherman; Razelle Kurzrock
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958

View more
  7 in total

Review 1.  Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Authors:  M G Castagna; S Cantara; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-06-27       Impact factor: 4.256

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.

Authors:  I Marturano; M Russo; A Spadaro; A Latina; P Malandrino; C Regalbuto
Journal:  J Endocrinol Invest       Date:  2015-06-13       Impact factor: 4.256

4.  [Oncological theranostics in nuclear medicine].

Authors:  Christina Laschinsky; Ken Herrmann; Wolfgang Fendler; Michael Nader; Harald Lahner; Boris Hadaschik; Patrick Sandach
Journal:  Radiologie (Heidelb)       Date:  2022-10

Review 5.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

6.  Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes.

Authors:  Aleksandra Kukulska; Jolanta Krajewska; Marzena Gawkowska; Ewa Paliczka-Cieslik; Daria Handkiewicz-Junak; Aleksandra Kropińska; Zbigniew Puch; Tomasz Olczyk; Jozef Roskosz; Barbara Jarzab
Journal:  Arch Med Sci       Date:  2020-08-03       Impact factor: 3.707

7.  Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.

Authors:  I Vardarli; F Weidemann; M Aboukoura; K Herrmann; I Binse; R Görges
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.